<DOC>
	<DOC>NCT01999413</DOC>
	<brief_summary>Pilot study of the efficacy and tolerance of the adjunction of a Fish oil emulsion to daunorubicin and cytarabine chemotherapy for the treatment of Acute MYeloblastic Leukemia of Younger patients (under 61 years) with high-risk cytogenetics.</brief_summary>
	<brief_title>Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients</brief_title>
	<detailed_description>Adjunction of a Fish oil emulsion OMEGAVEN to daunorubicin and cytarabine chemotherapy for the treatment of Acute MYeloblastic Leukemia of Younger patients.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Patient between 18 and 60 years old (less than 61 years old) With newly diagnosed with AML according to WHO classification: With 20% or more blasts in the bone marrow Patients with history of tumors other than myeloproliferative disorders or myelodysplastic syndromes, having received chemotherapy and/or radiotherapy without previous history of myelodysplastic syndromes are eligible for the present study Highrisk cytogenetics defined as one the following abnormalities : 5/5q, 7/7q, t(6,9), 11q23 abnormality excluding t(9;11), 3q abnormality,complex karyotype (&gt;3 abnormalites) Left ventricular ejection fraction (LVEF) &gt; 50% on echocardiography or multigated acquisition (MUGA) scan or similar radionuclide angiographic scan. Adequate liver function (all of the following) except if secondary to the leukemia: Total bilirubin below 1.5 x upper limit of normal (ULN), AST and ALT below 2.5 x ULN , gammaGT below 2.5 x ULN, Adequate kidney function (all of the following): Serum creatinine below 1.5 x ULN, Creatinine clearance above 50 mL/min (Cockroft and Gault formula) ECOG performance status &lt; or = 2. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and followup schedule. The patient must give written (personally signed and dated) informed consent before completing any studyrelated procedure which means assessment or evaluation that would not form part of the normal medical care of the patient. Affiliated to the French Social Security (Health Insurance). Previous allogeneic stem cell transplantation. Preexisting aplastic anemia Presence of favourable cytogenetics with t(8;21), t(15;17), or inv(16) Previous history of MDS or myeloproliferative neoplasm Uncontrolled active infection. History of arrythmia. Cardiac toxicity induced by another anthracycline administration Maximum cumulative dose reached for any anthracyclin Allergy to cytarabine, daunorubicin, fish or egg proteins10. Significant neurologic (grade &gt; 2) or psychiatric disorder, dementia or seizures. Clinical symptoms suggesting active central nervous system leukemia. Degenerative or toxic encephalopathy Severe complications of leukemia such as:Uncontrolled bleeding, Pneumonia with hypoxia or shock Prior total body irradiation &gt; 10 Gy. Known active HIV, Hepatitis B or C infection Pregnancy or breastfeeding Concomitant antiamarile vaccination (yellow fever) Concurrent treatment with any other anticancer therapy except Hydroxyurea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>high-risk cytogenetics</keyword>
	<keyword>younger patients</keyword>
	<keyword>Induction treatment</keyword>
	<keyword>OMEGAVEN</keyword>
</DOC>